RT Journal
A1 Bangalore S, Steg P, Bhatt DL
T1 Β-blocker use for patients with or at risk for coronary artery disease—reply
JF JAMA
JO JAMA
YR 2013
FD February 6
VO 309
IS 5
SP 438
OP 438
DO 10.1001/jama.2012.128872
UL http://dx.doi.org/10.1001/jama.2012.128872
AB 
The well-known fact that atenolol is ineffective has not translated into clinical practice—atenolol was the second top generic drug based on retail dollars in 2010.1 The data on β-blocker use in patients without heart failure are based on older agents and as a result, there is no guideline recommendation of a preferred β-blocker.